ReviewMedicinal research reviews2015
Toward a Cancer Drug of Fungal Origin.
Review in Medicinal research reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 84 citations in OpenAlex.
- Studies on the epipolythiodioxopiperazine alkaloid verticillin D: Scaled production, streamlined purification, and absolute configuration.Phytochemistry · 2025Article
- A Review Discussing Synthesis and Translational Studies of Medicinal Agents Targeting Sphingolipid Pathways.Biomolecules · 2025Review
- In Vivo and Clinical Studies of Natural Products Targeting the Hallmarks of Cancer.Handbook of experimental pharmacology · 2025Review
- Endophytic fungi: A future prospect for breast cancer therapeutics and drug development.Heliyon · 2024Review
- What are the 100 most cited fungal genera?Studies in mycology · 2024Article
- Advances on anticancer fungal metabolites: sources, chemical and biological activities in the last decade (2012-2023).Natural products and bioprospecting · 2024Article
- Chemical Constituents and Anticancer Activities of Marine-Derived FungusMolecules (Basel, Switzerland) · 2024Article
- Fusaric acid inhibits proliferation and induces apoptosis through triggering endoplasmic reticulum stress in MCF-7 human breast cancer cells.Mycotoxin research · 2023Article
- Paralemnalia thyrsoides-associated fungi: phylogenetic diversity, cytotoxic potential, metabolomic profiling and docking analysis.BMC microbiology · 2023Article
- Therapeutic vulnerabilities of cancer stem cells and effects of natural products.Natural product reports · 2023Review
- The Cytotoxic Properties of Extreme Fungi's Bioactive Components-An Updated Metabolic and Omics Overview.Life (Basel, Switzerland) · 2023Review
- Orellanine: From Fungal Origin to a Potential Future Cancer Treatment.Journal of natural products · 2023Review
- Apoptotic Janus-faced mycotoxins against thoracal and breast metastases.Apoptosis : an international journal on programmed cell death · 2023Review
- Newly synthesized methionine aminopeptidase 2 inhibitor hinders tumor growth.Drug delivery and translational research · 2023Article
- A Promising Natural Anticancer Compound Derived fromArchives of Razi Institute · 2023Article
- Neurospora crassa is a potential source of anti-cancer agents against breast cancer.Breast cancer (Tokyo, Japan) · 2022Article
- Cancer Microbiology.Journal of the National Cancer Institute · 2022Article
- Coriloxin Exerts Antitumor Effects in Human Lung Adenocarcinoma Cells.International journal of molecular sciences · 2022Article
- Anti-lung Cancer Marine Compounds: A Review.Therapeutic innovation & regulatory science · 2022Review
- Effects of Different Bud Thinning Methods on Nutritional Quality and Antioxidant Activities of Fruiting Bodies ofFrontiers in plant science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
Abstract
Although fungi produce highly structurally diverse metabolites, many of which have served as excellent sources of pharmaceuticals, no fungi-derived agent has been approved as a cancer drug so far. This is despite a tremendous amount of research being aimed at the identification of fungal metabolites with promising anticancer activities. This review discusses the results of clinical testing of fungal metabolites and their synthetic derivatives, with the goal to evaluate how far we are from an approved cancer drug of fungal origin. Also, because in vivo studies in animal models are predictive of the efficacy and toxicity of a given compound in a clinical situation, literature describing animal cancer testing of compounds of fungal origin is reviewed as well. Agents showing the potential to advance to clinical trials are also identified. Finally, the technological challenges involved in the exploitation of fungal biodiversity and procurement of sufficient quantities of clinical candidates are discussed, and potential solutions that could be pursued by researchers are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.